MEDICAM EVOLUX, EVOSTAR, EVOLIGHT AND EVOLASE PULSED LIGHT SYSTEM

K111350 · Medicam, Inc. · ONF · Sep 29, 2011 · General, Plastic Surgery

Device Facts

• Record ID: K111350
• Device Name: MEDICAM EVOLUX, EVOSTAR, EVOLIGHT AND EVOLASE PULSED LIGHT SYSTEM
• Applicant: Medicam, Inc.
• Product Code: ONF · General, Plastic Surgery
• Decision Date: Sep 29, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Indications for Use

The Medicam Evolux, Evostar and Evolight pulsed light systems (and included accessories) are indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue. It is intended for use for: Removal of unwanted hair from all skin types (640nm to 1200nm); Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (510nm to 1200nm); Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, erythema, leg veins(485 nm to 1200nm); and Treatment of benign cutaneous lesions including warts, scars and striae (420nm to 1200nm). The Medicam Evolase pulsed light system (and included accessories) is indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue. It is intended for use for: Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (1064nm to 1200nm); and Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, erythema, leg veins (532nm to 1200nm). The devices are intended for prescription use.

Device Story

Medicam Evolux, Evostar, Evolight, and Evolase are pulsed light systems emitting wide-spectrum light (420–1200 nm). Systems comprise a console with software/electronic controls, a color touch screen, and a handpiece with an integrated cooling system. Operated by clinicians in surgical/aesthetic settings. Device delivers light energy to target tissue to induce selective photothermolysis or coagulation for hair removal, vascular/pigmented lesion treatment, and scar/wart management. Clinicians use the touch screen to configure parameters; output affects tissue via thermal energy. Benefits include non-invasive treatment of various cutaneous conditions.

Clinical Evidence

No clinical data provided; substantial equivalence is based on design, functional features, and indications for use compared to legally marketed predicate devices.

Technological Characteristics

Pulsed light system; wavelength range 420–1200 nm; includes system console, electronic control boards, color touch screen, and handpiece with cooling system. Software-controlled energy delivery. Class II device.

Indications for Use

Indicated for surgical, aesthetic, and cosmetic applications requiring selective photothermolysis and hemostasis of soft tissue. Patient population includes individuals requiring treatment for unwanted hair, benign pigmented lesions (dyschromia, melasma, ephelides), benign cutaneous vascular lesions (port wine stains, hemangiomas, rosacea, erythema, leg veins), and benign cutaneous lesions (warts, scars, striae). Prescription use only.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• Profile BBL System (K032460)
• Quantum, Models SR, HR, DL (K020839)

Submission Summary (Full Text)

{0}------------------------------------------------

# KIII350

SEP 2 9 2011

## · Attachment 5

## 510(k) Summary

## As required by 21 CFR 807.92(c)

| Submitter | MEDICAM INC. |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Address | 7900 Jean-Brillon<br>Montréal, QC<br>Canada<br>H8N 2L5 |
| Phone | [phone] |
| Fax | [phone] |
| Contact Person | Philippe Amar<br>President |
| Summary Date | May 5, 2011 |
| Device Trade Name | Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light Systems |
| Device common name | Laser Powered Surgical Instrument (and Accessories) |
| Classification Name | Laser Surgical Instrument for use in General and Plastic Surgery and in<br>Dermatology (21 CFR 878.4810) |
| Legally Marketed<br>Predicate Devices | Profile BBL System (K032460)<br>Quantum, Models SR, HR, DL (K020839) |
| System Description | Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light Systems emit<br>intense wide spectrum emission with wavelength of 420 - 1200 nm.<br><br>It includes the following main components:<br>A system console (including software and electronic control boards);<br>A control and color touch screen; and |

{1}------------------------------------------------

| | Hand piece with cooling system. |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | The Medicam Evolux, Evostar and Evolight pulsed light systems (and included accessories) are indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue. |
| | It is intended for use for: |
| | Removal of unwanted hair from all skin types (640nm to 1200nm); |
| | Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (510nm to 1200nm); |
| | Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, erythema, leg veins(485 nm to 1200nm); and |
| | Treatment of benign cutaneous lesions including warts, scars and striae (420nm to 1200nm). |
| | The Medicam Evolase pulsed light system (and included accessories) is indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue. |
| | It is intended for use for: |
| | Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (1064nm to 1200nm); and |
| | Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, erythema, leg veins (532nm to 1200nm). |
| | The devices are intended for prescription use. |
| Substantial Equivalence | The Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light Systems shares the same indications for use, similar design and functional features and are therefore substantially equivalent to the above legally marketed predicate devices. |
| Safety and Effectiveness Information | The indications for use are based upon the indications for use from Predicate systems. Technologically, the Medicam Evolux, Evostar, Evolight |

KIU3SO- ..

{2}------------------------------------------------

K111350

. •

:

| | and Evolase Pulsed Light Systems are substantially equivalent to the listed predicate devices. Therefore, the risks and benefits for Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light System are comparable to the predicate devices. |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Conclusion | The Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light Systems share similar indications for use, design features and similar functional features as the currently marketed predicate devices and therefore are substantially equivalent to them. |

{3}------------------------------------------------

- CHATHAM INVESTMENT PARTNERS, LLC

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002

Medicam. Inc. % Mr. Philippe Amar President 7900 Jean-Brillon Montreal, Quebec, Canada H8N 2L5

SEP 2 9 2011

Re: K111350

Trade/Device Name: Medicam Evolus, Evostar, Evolight and Evolase Pulsed Light Systems Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: ONF Dated: September 23, 2011 Received: September 26, 2011

Dear Mr. Amar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, ilsting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations of eclass of (1 MF).
For discult of the controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 - Mr. Philippe Amar

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050,

ff you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/Centers0ffices/CDRH0ffices/ucm/1.se/ucm/1.phease/
the Conter for Designers offices/CDRH/CDRHOffices/ucm/1.5809.html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regions of artisting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll the [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Eric M. Keith

FS Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

### Attachment IV

#### Indications for Use Statement

K111350 510(k) Number:

#### Medicam Evolux, Evostar, Evolight and Evolase Pulsed Light Systems Device Name:

Indications for use:

The Medicam Evolux, Evostar and Evolight pulsed light systems (and included accessories) are indicated for use in surgical, aesthetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue.

It is intended for use for:

- A Removal of unwanted hair from all skin types (640nm to 1200nm);
- A Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (510nm to 1200nm);
- A Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, erythema, leg veins(485 nm to 1200nm); and
- A Treatment of benign cutaneous lesions including warts, scars and striae (420nm to 1200nm).

The devices are intended for prescription use.

*** Continued on Following Page ***

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CFRH Office of Device Evaluation (ODE)

| | (Division Sign-Off) |
|--|-----------------------------------------------------------|
| | Division of Surgical, Orthopedic, and Restorative Devices |

for mxnPrescription Use X (Per 21CFR801)

OR

Over-the-counter J

{6}------------------------------------------------

Indications for use:

#### *** Continued from Previous Page***

The Medicam Evolase pulsed light system (and included accessories) is indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue.

It is intended for use for:

- > Treatment of benign pigmented lesions including dyschromia, hyper pigmentation, melasma, ephelides (freckles) (1064nm to 1200nm); and
- Removal of benign cutaneous vascular lesions including port wine stains, hemangiomas, rosacea, A erythema, leg veins (532nm to 1200nm).

The device is intended for prescription use.

## (PLEASE DO NOT WRITE BELOW THIS LINE - CONȚINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CFRH Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

| Prescription Use<br>(Per 21CFR801) | X | OR | Over-the-counter Use |
|------------------------------------|---------|----|----------------------|
| 510(k) Number | K111350 | | |